Acyclovir and Tenofovir Disoproxil Interaction

Understanding the Acyclovir and Tenofovir Disoproxil Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Acyclovir belongs to the Antiviral (Nucleoside Analog) class and Tenofovir Disoproxil belongs to the Nucleotide Reverse Transcriptase Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These two drugs are both filtered out of the body by the kidneys, which can increase the risk of kidney strain when used at the same time. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Acyclovir has 7 total documented interactions on file in this dataset, and Tenofovir Disoproxil has 14. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your healthcare provider should monitor your kidney health to make sure the drugs are not causing harm. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Acyclovir or Tenofovir Disoproxil based on a web page, speak with your prescriber or pharmacist before making any change.